Press releases
- Geron Announces FDA Approval of RYTELO™ (imetelstat), a First-in-Class Telomerase Inhibitor, for the Treatment of Adult Patients with Lower-Risk MDS with Transfusion-Dependent Anemia
- Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Geron Corporation Reports First Quarter 2024 Financial Results and Business Highlights
- Geron to Announce First Quarter 2024 Financial Results on May 2, 2024
- Geron to Participate at Upcoming Investor Conferences in April
- Geron Corporation Announces Pricing of $150 Million Underwritten Offering of Common Stock and Pre-Funded Warrants
- Geron Announces FDA Oncologic Drugs Advisory Committee Votes in Favor of the Clinical Benefit/Risk Profile of Imetelstat for the Treatment of Transfusion-Dependent Anemia in Patients with Lower-Risk MDS
More ▼
Key statistics
On Friday, Geron Corp (0IV3:LSE) closed at 4.62, 7.70% below its 52-week high of 4.29, set on Apr 29, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | -- |
---|---|
High | -- |
Low | -- |
Bid | -- |
Offer | -- |
Previous close | 3.87 |
Average volume | 3.26k |
---|---|
Shares outstanding | 593.13m |
Free float | 592.62m |
P/E (TTM) | -- |
Market cap | 2.11bn USD |
EPS (TTM) | -0.3464 USD |
Data delayed at least 20 minutes, as of Jun 07 2024 16:32 BST.
More ▼